AMDL Announces New GOODNAK Consumer Anti-Aging Products for Use in Skin Renewal Treatments
May 30 2008 - 10:00AM
PR Newswire (US)
TUSTIN, Calif., May 30 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), http://www.amdl.com/ ,a world leader in specialty
pharmaceuticals with operations in Shenzhen, Jiangxi and Jilin,
China, announced today the launch of new products for its GOODNAK
anti-aging line. The company is releasing the new GOODNAK
formulations in partnership with JJB, the subsidiary of AMDL's
Chinese subsidiary Jade Pharmaceutical Inc. (JPI). Scheduled to be
released next month, the GOODNAK product includes Human Placental
Histosolution, and effective and key component in anti-aging
products which has been shown to give skin a youthful look by
increasing cell renewal and smoothening fine lines. JJB has applied
to Chinese regulatory authorities for product approval and
anticipates sanction this month. Based on the general market
information, the proposed pricing for the new GOODNAK products is
anticipated to be approximately (U.S.)$40.00 per unit with a 60%
gross profit margin. Frank Zhang, managing Director of JPI, stated
that, "the new GOODNAK consumer products are expected to be highly
popular and anticipated sales growth is expected to significantly
increase in 2008 and beyond. This product may also be extremely an
exceptionally good candidate for export to the North American and
European beauty care markets." About AMDL: AMDL, Inc. is a global
specialty pharmaceutical company. The Company is headquartered in
Tustin, California with operations in Shenzhen, Jiangxi, and Jilin,
China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI),
AMDL is devoted to the research, development, manufacture, and
marketing of diagnostic, pharmaceutical, nutritional supplement,
and cosmetic products currently in China. The company employs
approximately 320 people in the U.S. and China. More information
about AMDL and its products can be obtained at
http://www.amdl.com/. About Jade Pharmaceutical: JPI has access to
the fastest growing pharmaceutical and consumer market in the
world: China. AMDL, through its subsidiaries, Jade currently
manufactures large volume injection fluids, tablets and other
related products, holding licenses for 133 products. It also
manufactures 107 generic, over the counter and supplemental
pharmaceutical products under certified Chinese Good Manufacturing
Practice (CGMP) standards. IR Contact: Mr. Paul Knopick Direct:
949.707.5365 Voicemail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: Mr. Paul Knopick, +1-949-707-5365, +1-714-505-4460
voicemail Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024